Drugs for Osteoporosis

On this page

Osteoporosis Overview - Brittle Bones Battle

  • Definition: Low bone mass & microarchitectural deterioration, leading to ↑ bone fragility. WHO diagnostic criterion: T-score ≤ -2.5.
  • Major Risk Factors:
    • Advanced age
    • Postmenopausal status (↓ estrogen)
    • Long-term corticosteroid use
    • Smoking, excessive alcohol
  • Goals of Therapy:
    • Prevent fractures
    • ↑ Bone Mineral Density (BMD)
    • Reduce pain, maintain function

⭐ Most common osteoporotic fractures: vertebral, hip, and wrist.

Bisphosphonates - Mighty Mineral Binders

  • MOA: Pyrophosphate analogs; bind hydroxyapatite in bone, inhibiting osteoclast activity and bone resorption.
    • 📌 BPP: Bisphosphonates Prevent Pores.
  • Key Agents:
    • Oral: Alendronate, Risedronate, Ibandronate
    • IV: Zoledronic acid, Pamidronate
  • Oral Administration:
    • Empty stomach (poor absorption).
    • Full glass of plain water.
    • Remain upright for 30-60 min (Alendronate/Risedronate 30 min; Ibandronate 60 min) to prevent esophagitis.
  • Major ADRs:
    • Esophagitis ⚠️ (oral)
    • Osteonecrosis of the Jaw (ONJ)
    • Atypical femoral fractures (long-term use)
    • Hypocalcemia; Flu-like symptoms (IV)
  • ⭐

    Zoledronic acid is given once yearly IV for osteoporosis treatment.

oka

SERMs & Denosumab - Targeted Bone Defenders

FeatureRaloxifene (SERM)Denosumab
MOAEstrogen agonist on bone; antagonist on breast & uterusMAb vs RANKL; inhibits osteoclast formation & survival
Benefits↓ Vertebral fractures; ↓ invasive breast cancer riskBroad ↓ fracture risk (vertebral, hip, non-vertebral)
AdminOralSC q6 months
Key ADRsHot flashes, ↑ VTE risk (DVT/PE)Hypocalcemia, skin issues, ONJ, atypical femoral fractures
📌 MnemonicRaloxifene: Risk (VTE) vs Reward (bone/breast)Denosumab: Deactivates osteoclasts via RANKL Directly

Anabolic Agents & Calcitonin - Bone Growth Boosters

  • Anabolic Agents: Stimulate new bone formation.

    • Teriparatide, Abaloparatide: Recombinant PTH analogues.
      • MOA: Intermittent exposure stimulates osteoblasts > osteoclasts, ↑ bone mass.
      • Use: Severe osteoporosis, patients at high fracture risk. Max 2 years therapy.
      • ADRs: Hypercalcemia, orthostatic hypotension, leg cramps.
      • ⚠️ BBW: Osteosarcoma risk (rats); avoid in Paget's disease, prior skeletal radiation.

    ⭐ Teriparatide treatment should be followed by an anti-resorptive agent to maintain BMD gains.

  • Calcitonin (Salmon):

    • MOA: Directly inhibits osteoclasts, ↓ bone resorption; provides analgesic effect.
    • Forms: Nasal spray, injection.
    • Use: Limited efficacy for osteoporosis; mainly for pain relief from acute vertebral compression fractures.

Loading diagram…

High‑Yield Points - ⚡ Biggest Takeaways

  • Bisphosphonates (e.g., Alendronate) are first-line agents, inhibiting osteoclast activity; key risks include ONJ and atypical femoral fractures. Specific administration is crucial.
  • Denosumab, an anti-RANKL monoclonal antibody, potently inhibits osteoclast function; administered as an SC injection every 6 months.
  • Teriparatide (recombinant PTH) is an anabolic agent that stimulates osteoblast activity and bone formation; reserved for severe osteoporosis.
  • Raloxifene, a SERM, inhibits bone resorption; it increases the risk of DVT/PE but decreases the risk of invasive breast cancer.
  • Romosozumab, an anti-sclerostin antibody, has a dual effect: it increases bone formation and decreases bone resorption.
  • Adequate Calcium and Vitamin D supplementation is essential alongside all pharmacological therapies for osteoporosis.

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Drugs for Osteoporosis

  1. 1. Which of the following antidiabetic drugs (other than insulin) is indicated as adjunct therapy for the management of both type I and type II diabetes mellitus?

    • A. Acarbose
    • B. Pramlintide
    • C. Glimepiride
    • D. Metformin
    Show answer

    Answer: B. Pramlintide

    Pramlintide - Pramlintide is an amylin analogue indicated as adjunctive therapy to insulin in both type 1 and type 2 diabetes. - It slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety, thereby improving postprandial glycemic control and reducing insulin requirements. Acarbose - Acarbose delays intestinal carbohydrate absorption and is used principally in type 2 diabetes. Although it has been studied as an adjunct in type 1 diabetes, it does not have the specific established adjunct-to-insulin indication in both types that identifies pramlintide. Glimepiride - Glimepiride is a sulphonylurea that stimulates insulin secretion from functioning pancreatic beta cells. It is used in type 2 diabetes and is not indicated for type 1 diabetes with absolute insulin deficiency. Metformin - Metformin reduces hepatic glucose production and improves insulin sensitivity. It may be used off-label in selected insulin-resistant patients with type 1 diabetes, but it does not have pramlintide’s specific established adjunct-to-insulin indication in both diabetes types.

  2. 2. A 60-year-old postmenopausal woman has DXA-confirmed osteoporosis after a low-trauma Colles fracture, without vertebral fractures or other very-high-risk features. All are appropriate routine treatment statements EXCEPT:

    • A. Oral calcium with cholecalciferol supplementation
    • B. Total calcium intake of twelve hundred mg/day
    • C. Bisphosphonate reassessment after three to five years
    • D. Routine teriparatide before bisphosphonates
    Show answer

    Answer: D. Routine teriparatide before bisphosphonates

    Routine teriparatide before bisphosphonates is the exception because anabolic-first treatment is not routinely indicated in the specified patient without very-high-risk features. Oral calcium with cholecalciferol supplementation supports adequate mineral availability during osteoporosis treatment. Bisphosphonate reassessment after three to five years guides continuation or a selective drug holiday according to treatment and fracture risk. Total calcium intake of twelve hundred mg/day is an accepted target for postmenopausal women and includes dietary calcium.

  3. 3. During documented hypoglycemia with an inappropriately elevated serum insulin concentration, which of the following best distinguishes surreptitious insulin injection from an insulinoma?

    • A. Serum glucose level
    • B. Serum beta-hydroxybutyrate
    • C. C-peptide levels
    • D. Insulin antibodies
    Show answer

    Answer: C. C-peptide levels

    C-peptide levels During hypoglycemia, injected insulin produces an elevated measured insulin concentration with suppressed endogenous insulin secretion and low C-peptide. Insulinoma produces inappropriately nonsuppressed insulin and C-peptide concentrations; these need not exceed the laboratory reference intervals. As described in Harrison’s approach to hypoglycemia, sulfonylureas and meglitinides can mimic this endogenous pattern, so a secretagogue screen is required when that exposure is possible. Serum glucose level; Serum beta-hydroxybutyrate Glucose and beta-hydroxybutyrate can be low in both conditions. Insulin antibodies Insulin antibodies can occur after insulin exposure or in insulin autoimmune syndrome and are not a reliable discriminator between injected-insulin hypoglycemia and insulinoma.

  4. 4. Bisphosphonates are routinely used as first-line therapy in all of the following conditions EXCEPT:

    • A. Postmenopausal osteoporosis
    • B. Paget's disease of bone
    • C. Vitamin D intoxication
    • D. Hypercalcemia of malignancy
    Show answer

    Answer: C. Vitamin D intoxication

    Vitamin D intoxication - Vitamin D intoxication causes hypercalcemia primarily by increasing intestinal absorption of calcium and phosphate rather than by excessive osteoclast-mediated bone resorption. - Bisphosphonates act mainly on bone resorption and do not block intestinal calcium absorption; hydration and glucocorticoids are used in vitamin D toxicity. Bisphosphonates may be used for severe or refractory hypercalcemia but are not routine first-line therapy. Hypercalcemia of malignancy - Hypercalcemia of malignancy may result from osteolytic metastases or PTH-related peptide, causing increased osteoclast-mediated bone resorption. - Intravenous zoledronate or pamidronate inhibits osteoclast activity and is used to reduce calcium levels in this setting. Postmenopausal osteoporosis - Postmenopausal osteoporosis involves increased osteoclast activity associated with estrogen deficiency and accelerated bone loss. - Drugs such as alendronate inhibit bone resorption, increase bone mineral density, and reduce fracture risk. Paget's disease of bone - Paget's disease of bone causes excessive and disorganized bone remodeling with a markedly increased rate of bone turnover. - Bisphosphonates, particularly zoledronate, suppress osteoclast activity and are first-line treatment for active Paget’s disease.

  5. 5. All of the following statements about diazoxide are true EXCEPT:

    • A. Potassium channel opener
    • B. Used as an antihypertensive
    • C. Used in insulinoma therapy
    • D. Causes severe hypoglycemia
    Show answer

    Answer: D. Causes severe hypoglycemia

    Causes severe hypoglycemia - Diazoxide does not cause severe hypoglycemia; it inhibits insulin release by opening KATP channels in pancreatic beta cells. - Reduced insulin secretion instead produces hyperglycemia, which is why diazoxide treats hypoglycemia associated with insulinoma and represents the exception. Potassium channel opener - Diazoxide opens ATP-sensitive potassium channels (KATP) in pancreatic beta cells and vascular smooth muscle, producing membrane hyperpolarization. - This statement is true because KATP-channel opening inhibits beta-cell depolarization and insulin secretion, while relaxing vascular smooth muscle. Used as an antihypertensive - Diazoxide has antihypertensive activity because potassium-channel opening hyperpolarizes vascular smooth muscle and causes potent vasodilation. - Although rarely used now, diazoxide was historically administered intravenously for hypertensive emergencies, so this statement is true. Used in insulinoma therapy - Diazoxide is used in insulinoma because it suppresses pancreatic insulin release and can reduce hypoglycemia from excessive insulin secretion. - It is particularly useful for controlling hypoglycemia in inoperable insulinomas or leucine-sensitive hypoglycemia, making this statement true.

  6. 6. A 60-year-old man presents with pain in multiple bones and increasing hat size. Several affected bones are warm to touch. Serum calcium, phosphate, and PTH are normal, but ALP is markedly elevated. What is the most likely diagnosis?

    • A. Multiple myeloma
    • B. Osteosarcoma
    • C. Osteomalacia
    • D. Paget disease
    Show answer

    Answer: D. Paget disease

    Paget disease - Increased hat size, bone pain, and warmth indicate skull involvement with high bone turnover and hypervascularity, characteristic of Paget disease. - Markedly elevated ALP with normal calcium, phosphate, and PTH supports active Paget disease rather than a generalized mineralization or parathyroid disorder. Osteosarcoma - Osteosarcoma usually causes localized pain and a mass, classically arising in the metaphysis of a long bone near the knee. - The widespread skeletal symptoms and increased hat size are not typical of osteosarcoma, whereas Paget disease commonly produces these findings in older adults. Multiple myeloma - Multiple myeloma commonly causes anemia, renal failure, and hypercalcemia through lytic bone disease; the normal calcium level makes it less likely here. - A serum or urine M-protein is characteristic, while ALP is usually normal or only mildly elevated unless a pathological fracture is present. Osteomalacia - Osteomalacia can occur with normal serum calcium, so normal calcium alone does not exclude it; vitamin D-deficiency osteomalacia more typically produces low phosphate and secondary elevation of PTH, unlike the normal phosphate and PTH reported here. - Although ALP may rise in osteomalacia, skull expansion with increased hat size and warm, thickened bones is not typical of this condition.

  7. 7. An intrauterine scan at the 13th week of pregnancy showed a fetus with multiple long bone fractures. What is commonly associated with this finding?

    • A. Osteogenesis imperfecta
    • B. Marfan syndrome
    • C. Achondroplasia
    • D. Congenital hypothyroidism
    Show answer

    Answer: A. Osteogenesis imperfecta

    Osteogenesis imperfecta - Osteogenesis imperfecta classically causes multiple long-bone fractures detected early in pregnancy because of marked bone fragility. - It is primarily caused by mutations affecting type I collagen, resulting in defective bone formation and skeletal fractures. Congenital hypothyroidism - Congenital hypothyroidism involves severely deficient thyroid hormone production in a newborn. - Although it can cause growth retardation and developmental disability, it is not associated with multiple prenatal long-bone fractures. Marfan syndrome - Marfan syndrome is a connective-tissue disorder associated with tall stature, long limbs and fingers, and aortic root dilation. - Although it affects the skeleton through fibrillin-1 abnormalities, prenatal multiple long-bone fractures are not its characteristic presentation. Achondroplasia - Achondroplasia is a skeletal dysplasia causing disproportionate short limbs with a relatively normal-sized trunk through an FGFR3 mutation. - It affects longitudinal bone growth but typically does not produce multiple fractures in long bones during early pregnancy.

  8. 8. A 65-year-old postmenopausal woman has osteoporosis without previous fragility fractures. Renal function is normal, and there is no oesophageal disease. Which is the preferred initial drug?

    • A. Raloxifene
    • B. Salmon calcitonin
    • C. Alendronate
    • D. Oestrogen
    Show answer

    Answer: C. Alendronate

    Alendronate is a first-line bisphosphonate for uncomplicated postmenopausal osteoporosis because it reduces osteoclast-mediated bone resorption and fragility-fracture risk. - Bisphosphonates are first-line therapy because they have proven efficacy in reducing fragility-fracture risk in post-menopausal osteoporosis. - They inhibit osteoclast activity, reducing bone resorption and thereby helping preserve or increase bone mineral density. Raloxifene - Raloxifene is a selective estrogen receptor modulator that may prevent vertebral fractures and is useful in selected patients, but it is generally not the preferred initial treatment. - Its fracture-reduction efficacy is less comprehensive than bisphosphonates, particularly for non-vertebral fractures, so it is usually considered an alternative when bisphosphonates are unsuitable. Oestrogen - Oestrogen can reduce bone loss, but it is not routinely first-line therapy because osteoporosis treatment must consider its broader systemic risks. - Hormone replacement therapy may increase risks of breast cancer, cardiovascular events, and stroke, so it is generally reserved for women with significant menopausal symptoms or selected contraindications to other treatments. Salmon calcitonin - Salmon calcitonin may be used short-term for pain relief after acute vertebral fractures or when other therapies are not tolerated, but it is not preferred initially. - Its fracture-prevention efficacy is less robust than that of bisphosphonates, making it unsuitable as routine first-line treatment.

  9. 9. Which of the following is NOT seen in non-ketotic hyperosmolar coma?

    • A. Kussmaul respiration
    • B. Type 2 diabetes mellitus
    • C. Advanced age
    • D. Insidious onset
    Show answer

    Answer: A. Kussmaul respiration

    Kussmaul respiration - Kussmaul respiration is a deep, rapid respiratory compensation for metabolic acidosis, classically seen in diabetic ketoacidosis rather than HHS. - In HHS, residual endogenous insulin suppresses lipolysis and ketone formation, so significant ketoacidosis and the associated Kussmaul respiration are generally absent. Type 2 diabetes mellitus - HHS is classically associated with type 2 diabetes mellitus, in which residual insulin limits ketogenesis but is insufficient to prevent severe hyperglycemia. - This distinguishes HHS from diabetic ketoacidosis, which is more strongly associated with absolute insulin deficiency, typically in type 1 diabetes. Advanced age - HHS is commonly seen in elderly patients, who may have unrecognized diabetes and reduced access to water or impaired thirst responses. - Older adults are also vulnerable to precipitating illnesses such as infection, stroke, or myocardial infarction, which can worsen hyperglycemia and dehydration. Insidious onset - HHS typically has an insidious onset, developing over days to weeks rather than the rapid progression commonly seen in diabetic ketoacidosis. - The gradual course permits profound dehydration and hyperosmolality, often producing marked neurological symptoms such as confusion, seizures, or coma.

  10. 10. Which of the following is recombinant parathyroid hormone (rPTH) used in osteoporosis treatment?

    • A. Teriparatide
    • B. Calcipotriol
    • C. Denosumab
    • D. Calcitriol
    Show answer

    Answer: A. Teriparatide

    Teriparatide - Teriparatide is recombinant human parathyroid hormone (rPTH) used as an anabolic treatment for osteoporosis. - Intermittent teriparatide stimulates osteoblastic activity and new bone formation, increasing bone mineral density and reducing fracture risk. Calcitriol - Calcitriol is the active form of vitamin D, promoting intestinal calcium absorption and supporting bone mineralization rather than acting as recombinant parathyroid hormone. - Although used in hypocalcemia and kidney failure–related metabolic bone disease, calcitriol is not the primary anabolic osteoporosis treatment described here. Denosumab - Denosumab is a monoclonal antibody against RANKL, inhibiting osteoclast formation and function to reduce bone resorption. - It is used for osteoporosis, but its antiresorptive mechanism distinguishes it from recombinant parathyroid hormone and its anabolic effect on osteoblasts. Calcipotriol - Calcipotriol is a vitamin D analog primarily used topically to regulate keratinocyte proliferation and differentiation in psoriasis. - Its dermatological use and mechanism in skin cell regulation do not correspond to recombinant parathyroid hormone therapy for osteoporosis.

Flashcards: Drugs for Osteoporosis

  1. 1. is contraindicated in patients with prior history of radiation, for treatment of osteoporosis.

    Show answer

    Teriparatide

  2. 2. Thyroid, Pituitary, & Adrenal _____ are a class of drugs that are useful in the treatment and prevention of _____ osteoporosis

    Show answer

    Selective estrogen receptor modulators (SERMs) · postmenopausal

  3. 3. Teriparatide increases the risk of

    Show answer

    osteosarcoma

  4. 4. Denosumab prevents _____ activation by binding _____ expressed on osteoblasts

    Show answer

    osteoclast · RANKL

  5. 5. Which SGLT2 inhibitor is associated with an increased risk of fractures?

    Show answer

    Canagliflozin

  6. 6. Drug of choice for post menopausal osteoporosis is

    Show answer

    Bisphosphonates

  7. 7. _____ is a monoclonal antibody against _____, useful in the treatment of osteoporosis.

    Show answer

    Denosumab · RANKL

  8. 8. One rare side effect of _____ and _____ is _____ (rare)

    Show answer

    bisphosphonates · denosumab · osteonecrosis of the jaw

  9. 9. gossypol is _____

    Show answer

    a male contraceptive

  10. 10. EZY pill contains _____

    Show answer

    LNG 1.5 mg — LNG is progesterone

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF